Drug Trial Radar · NCT00075998
The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)
Last checked: Nov 20, 2026Latest source record: Jul 2, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
826
Actual
Start
Dec 2003
Primary completion
Not stated
Study completion May 2007
Sponsor
- Lead sponsor
- InterMuneIndustry
- Sponsor type
- Industry
- First posted
- Jan 14, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
* Purpose: A phase 3, randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of 200 µg of recombinant Interferon gamma-1b administered by subcutaneous (SC) injection, compared with placebo, in patients with IPF * Enrollment: Approximately 800 patients will be enrolled from approximately 80 centers in North America and Europe * Randomization: 2:1 active-to-placebo ratio * Duration: at least 2 years active drug or placebo (rescue therapy will be permitted for patients who meet predefined criteria)
Conditions
- Idiopathic Pulmonary Fibrosis
- Lung Disease
- Pulmonary Fibrosis
Interventions
Interferon gamma-1b ("Actimmune")Drug
200 mcg, SQ, 3x per week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Survival time from randomization to treatment completion visit, or, end of treatment period, or, last known vital status.Time frame: 3.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
InterMune, Inc.
Brisbane, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.